- Scinai Immunotherapeutics’ wholly owned subsidiary has signed a development and clinical manufacturing agreement with a U.S.-based, Nasdaq-listed biopharmaceutical company, including approximately $5.1 million in committed base service fees.
- Scinai’s committed customer orders across its Jerusalem and Yavne operations have reached approximately $7.6 million, up around 300% from $1.9 million at the end of 2025.
Scinai Immunotherapeutics has signed a development and clinical manufacturing agreement through its wholly owned subsidiary, Scinai Biopharma Services Ltd., with a U.S.-based, Nasdaq-listed biopharmaceutical company. The agreement expands a previously disclosed customer engagement and includes approximately $5.1 million in committed base service fees, subject to performance and the agreement’s terms, including applicable termination rights.
The services are expected to contribute to revenue during 2026 and 2027 as the relevant performance obligations are satisfied, with stability services continuing beyond 2027. Advance and milestone payments for the committed services are expected to support cash flow and working capital during project execution.
Following the agreement, Scinai’s committed customer orders across its Jerusalem and Yavne operations reached approximately $7.6 million. This represents an increase of approximately 300% from $1.9 million at year-end 2025 and more than double the approximately $3.1 million reported as of August 16, 2026. The total excludes future pass-through purchases and associated markups until ordered and committed, as well as potential additional manufacturing activities.
“The agreement expands the company’s contracted CDMO business and supports its strategy of providing bespoke services to international customers. It provides greater visibility into the company’s manufacturing workload for 2027, combining development and investigational new drug (IND)-enabling activities underway in 2026 with a clinical manufacturing program planned to begin in January 2027.”
Amir Reichman, CEO of Scinai
Scinai said it aims to convert these commitments into revenue, higher facility utilization, and improved operating performance while continuing to grow its business. The company also identified potential additional clinical supply and eventual commercial manufacturing as possible extensions of its customer relationships.
